BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...

June 08, 2026 | News

Innovent's Arcotatug Tavatecan Meets Phase 3 Endpoint in Advanced Gastric Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 05, 2026 | News

ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer

ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...

June 02, 2026 | News

Pfizer And Innovent Biologics Forge Global Oncology Alliance Covering 12 Cancer Programs

Pfizer Inc. and Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the r...

June 01, 2026 | News

Leica Biosystems Expands AstraZeneca And Daiichi Sankyo Collaboration To Advance AI Driven Lung Cancer Biomarker Research

Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions,announced an expansion of its strategic coll...

June 01, 2026 | News

Dizal Secures Priority Review In China For ZEGFROVY In First Line EGFR Exon20ins NSCLC

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced...

May 29, 2026 | News

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ingenia Therapeutics Secures KRX Approval For IPO Amid Advancing TIE2 Targeted Pipeline

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has receive...

May 26, 2026 | News

HistoSonics Secures Taiwan Approval For Edison Histotripsy System

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, announced it has received approval from the Taiwan...

May 21, 2026 | News

Leads Biolabs Secures China Phase III Approval For Opamtistomig In First Line EP NEC Treatment

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibod...

May 20, 2026 | News

ImmunityBio Secures Exclusive US Rights To Tokyo Strain BCG To Address Chronic Bladder Cancer Treatment Shortage

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo...

May 19, 2026 | News

Racura Oncology Receives Positive Safety Review Committee Recommendation To Advance CPACS Trial In Advanced Solid Tumours

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced soli...

May 18, 2026 | News

Sichuan Kelun-Biotech Biopharmaceutical Secures China IND Clearance For PD 1 x VEGF Bispecific SKB118 In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

May 14, 2026 | News

Stay Connected